register

News - Pharmaceuticals

Pfizer appoints Anne Harris Managing Director, Australia & New Zealand

Health Industry Hub | March 4, 2020 |

Pharma News: Pfizer has announced the appointment of Anne Harris to the role of Managing Director for Pfizer Australia and New Zealand who will officially commence in the role immediately, based in Sydney.

Most recently, Ms Harris was Commercial Lead for Pfizer’s Vaccines Business Unit for Developed Asia (Australia, New Zealand and Korea) for the past three years.  

Ms Harris brings 25 years experience in the pharmaceutical industry beginning her career as a medical representative in Australia, and has held a range of commercial roles across a variety of regions, with increasing leadership responsibility. 

She started in Pfizer’s Australia and New Zealand organisation in 1999 in management roles in training, sales, human resources and commercial effectiveness. Ms Harris has also worked in Europe, Asia and Emerging Markets in regional portfolio and digital marketing roles, including new product planning.  

During her time as Pfizer Vaccines Lead for Developed Asia, Anne worked to ensure that meningococcal and pneumococcal vaccines are available through National Immunisation Programs, including immunisation for indigenous and high-risk populations.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture measure up in the Australian Pharma industry? Get the benchmark report by contacting us.

“I am extremely humbled and honoured to be appointed to the role,” Ms Harris said.   

“Pfizer has a proud history in Australia and New Zealand and we have more than 1,600 passionate colleagues across these markets who are focused on our goal of delivering medicines to patients who need them.

“Our business has gone through some significant change in recent years with our move to Barrack Place in Sydney and our focus on our research pipeline.

“I also look forward to ensuring Pfizer’s important work in shaping the policy and advocacy environment positions of our industry to provide the best health outcomes for more Australians continues”, Ms Harris said.

Out-going Pfizer Australia and New Zealand Managing Director Melissa McGregor said it is terrific to see talented leaders of Anne’s calibre moving into new leadership opportunities within Pfizer.  

“Anne will continue our commitment to work closely with all relevant stakeholders, to help enable people across Australia and New Zealand to have better access to the medicines and therapies they need”, Ms McGregor said. 

Ms Harris assumes the role from Melissa McGregor, who is leaving Australia for Madrid to take up a new responsibility with Pfizer Europe as Vice President, European Hospital Business this month.   

In the meantime, Ms McGregor remains committed to the success of Pfizer in Australia and New Zealand and ensuring a smooth transition in leadership.   

“I am inspired by Melissa’s remarkable passion and dedication to serving patients, as well as the industry through her tenure as Medicines Australia deputy chair and founding member of PAIG”, Ms Harris said. 

“I thank Melissa for her tremendous leadership and contribution to the Australian and New Zealand Pfizer business over the past four years, and I look forward to building upon the strong legacy that she leaves behind,” she said. 

Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


Digital & Innovation

Health sector faces new privacy obligations

Health sector faces new privacy obligations

Health Industry Hub | September 11, 2026 |

Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]

More


News - Pharmaceuticals

TGA approves new antibiotic but AMR blind spot remains a critical concern

TGA approves new antibiotic but AMR blind spot remains a critical concern

Health Industry Hub | September 11, 2026 |

The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]

More


News - MedTech & Diagnostics

BCAL Diagnostics rejects merger speculation

BCAL Diagnostics rejects merger speculation

Health Industry Hub | September 11, 2026 |

ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]

More


News - Pharmaceuticals

Australia backs infectious disease innovation as US funding faces more cuts

Australia backs infectious disease innovation as US funding faces more cuts

Health Industry Hub | September 11, 2026 |

Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]

More


This content is copyright protected. Please subscribe to gain access.